SALBUTAMOL (US, ALBUTEROL)

sal-byoo-tah-mole / al byoo' ter ole

PCaution 

when used during lactation  - Caution when used during pregnancy

LCaution when used during lactation  - Caution when used during lactation

Molecule Info

Indication(s) & usage
Bronchospasm

Salbutamol is indicated for the treatment or prevention of bronchospasm in patients 4 years of age and older with reversible obstructive airway disease.

Exercise-Induced Bronchospasm

Salbutamol is indicated for the prevention of exercise-induced bronchospasm in patients 4 years of age and older.

Tablet/Syrup: Relief of bronchospasm in bronchial asthma of all types, chronic bronchitis and emphysema.
Syrup: Oral therapy for children or for those adults who prefer liquid medicines.
Respiratory Solution: Treatment of severe acute asthma (status asthmaticus) and other forms of bronchospasm. Nebule: Treatment of severe acute asthma (status asthmaticus) and routine management of chronic bronchospasm.
Evohaler: Relief and prevention of asthma symptoms. Ventolin evohaler should be used to relieve symptoms when they occur and to prevent them in those circumstances recognised by the patient to precipitate an asthma attack (eg, before exercise or unavoidable allergen exposure).
Relief medication in mild, moderate or severe asthma, provided that reliance on it does not delay the introduction and use of regular inhaled corticosteroid therapy.
Ampoule: Relief of severe bronchospasm associated with asthma or bronchitis and for the treatment of status asthmaticus.
Management of uncomplicated premature labour in the last trimester of pregnancy.

Dosage & administration

As there may be adverse effects associated with excessive dosing, the dosage or frequency of administration should only be increased on medical advice.
Tablet: Adults: Usual Effective Dose: 4 mg 3 or 4 times/day. If adequate bronchodilatation is not obtained, each single dose may be gradually increased to as much as 8 mg. However, it has been established that some patients obtain adequate relief with 2 mg 3 or 4 times daily.
Children >12 years: 2-4 mg; 6-12 years: 1 tab (2 mg); 2-6 years: Â½-1 tab (1-2 mg). To be administered 3 or 4 times daily.
Ventolin is well tolerated by children so that, if necessary, these doses can be cautiously increased.
Elderly or Patients known to be Unusually Sensitive to β-Adrenergic Stimulant Drugs: It is advisable to initiate treatment with 2 mg 3 or 4 times/day.
In the management of premature labour, after uterine contractions have been controlled by IV infusion of Ventolin and the infusion has been withdrawn, maintenance therapy can be continued with oral Ventolin. The usual dosage is 4 mg 3 or 4 times daily.
Syrup: Adults: 10 mL 3 or 4 times a day. Children: >12 years: 5-10 mL; 6-12 years: 5 mL; 2-6 years: 2.5-5 mL. To be taken 3 or 4 times a day.
Dilution: Ventolin syrup does not contain sugars. It may be diluted with purified water BP. The resulting mixture should be protected from light and used within 28 days. A 50% v/v dilution of Ventolin syrup has been shown to be adequately preserved against microbial contamination. However, to avoid the possibility of introducing excessive microbial contamination, the purified water used for dilution should be recently prepared or alternatively, it should be boiled and cooled immediately before use. Dilution of Ventolin syrup with syrup BP or sorbitol solution is not recommended as this may result in precipitation of the cellulose-thickening agent. Admixture of Ventolin syrup with other liquid preparations is not recommended.
Respiratory Solution: By Intermittent Administration: Adults: 0.5-1 mL (2.5-5 mg of salbutamol) should be diluted to a final volume of 2 or 2.5 mL with normal saline for injection. The resulting solution is inhaled from a suitably driven nebuliser until aerosol generation ceases. Using a correctly matched nebuliser and driving source, this should take about 10 min.
Ventolin Respiratory solution may be used undiluted for intermittent administration. For this, 2 mL of Ventolin Respiratory solution (10 mg salbutamol) is placed in the nebuliser and the patient allowed to inhale the nebulised solution until bronchodilatation is achieved. This usually takes 3-5 min.
Some adult patients may require higher doses of salbutamol, up to 10 mg, in which case nebulisation of the undiluted solution may continue until aerosol generation ceases.
Children: The same mode of administration for intermittent administration is also applicable to children.
Usual Dose: Children <12 years: 0.5 mL (2.5 mg salbutamol) diluted to 2 or 2.5 mL with normal saline for injection. Some children may however require higher doses of salbutamol up to 5 mg.
Clinical efficacy of nebulised salbutamol in infants <18 months is uncertain. As transient hypoxaemia may occur, supplemental oxygen therapy should be considered.
By Continuous Administration: Ventolin Respiratory solution is diluted with normal saline for injection to salbutamol 50-100 mcg/mL (1-2 mL solution made up to 100 mL with diluent). The diluted solution is administered as an aerosol by a suitably driven nebuliser. The usual rate of administration is 1-2 mg/hr.
Salbutamol has a duration of action of 4-6 hrs in most patients.
Ventolin Respiratory solution is to be used with a Respiratory or nebuliser, only under the direction of a physician.
The solution must not be injected.
Delivery of the aerosol may be by facemask, "T" piece or via an endotracheal tube. Intermittent positive pressure ventilation may be used but is rarely necessary. When there is a risk of anoxia through hypoventilation, oxygen should be added to the inspired air.
As many nebulisers operate on a continuous flow basis, it is likely that nebulised drug will be released in the local environment. Ventolin Respiratory solution should therefore be administered in a well ventilated room, particularly in hospitals when several patients may be using nebulisers at the same time.
Any unused solution in the chamber of the nebuliser must be discarded.
Dilution: Ventolin Respiratory solution may be diluted with sterile normal saline.
Evohaler: Evohaler is administered by the oral inhaled route only.
Relief of Acute Bronchospasm: Adults: 100 or 200 mcg.
Children: 100 mcg; the dose may be increased to 200 mcg if required.
Prevention of Allergen- or Exercise-Induced Bronchospasm: Adults: 200 mcg before challenge.
Children: 100 mcg before challenge; the dose may be increased to 200 mcg if required.
Chronic Therapy: Adults and Children: Up to 200 mcg 4 times daily.
On demand use of Ventolin should not exceed 4 times daily. Reliance on such supplementary use or a sudden increase in dose indicates deteriorating asthma (see Precautions).
Salbutamol has a duration of action of 4-6 hrs in most patients.
In patients who find coordination of a pressurised metered-dose inhaler difficult, a volumatic spacer may be used with evohaler.
Babies and young children may benefit from use of the babyhaler spacer device with evohaler.
Instructions for Use/Handling: Testing the Inhaler: Before using the inhaler for the 1st time, remove the mouthpiece cover by gently squeezing the sides of the cover, shake the inhaler well and release 2 puffs into the air to make sure that it works. If it has not been used for several days, shake it well and release 1 puff into the air to make sure that it works.
Using the Inhaler: 1. Remove the mouthpiece cover by gently squeezing the sides of the cover.
2. Check the inside and outside of the inhaler including the mouthpiece for the presence of loose objects.
3. Shake the inhaler well to ensure that any loose objects are removed and that the contents of the inhaler are evenly mixed.
4. Hold the inhaler upright between fingers and thumb with the thumb on the base, below the mouthpiece.
5. Breathe-out as far as is comfortable and then place the mouthpiece in the mouth between the teeth and close lips around it but do not bite it.
6. Just after starting to breathe-in through the mouth, press down on the top of the inhaler to release salbutamol while still breathing-in steadily and deeply.
7. While holding breath, take the inhaler from the mouth and take the finger from the top of the inhaler. Continue holding breath for as long as is comfortable.
8. If to take further puffs, keep the inhaler upright and wait about ½ min before repeating steps 3-7.
9. Replace the mouthpiece cover by firmly pushing and snapping the cap into position.
Note: Do not rush stages 5, 6 and 7. It is important that the patient starts to breathe-in as slowly as possible just before operating the inhaler. Practise in front of a mirror for the first few times. If a 'mist' is seen coming from the top of the inhaler or the sides of the mouth, start again from stage 2.
If the doctor has given different instructions for using the inhaler, follow them carefully. Tell the doctor if there are any difficulties.
Cleaning: The inhaler should be cleaned at least once a week.
Remove the metal canister from the plastic casing of the inhaler and remove the mouthpiece cover. Rinse the actuator thoroughly under warm running water. Dry the actuator thoroughly inside and out. Replace the metal canister and mouthpiece cover.
Do not put the metal canister into water.
Nebule: Adults and Children: A suitable starting dose of salbutamol by wet inhalation is 2.5 mg. This may be increased to 5 mg.
Treatment may be repeated 4 times daily.
Ventolin nebules are intended to be used undiluted. However, if prolonged delivery time is desirable (>10 min), dilution using normal saline for injection as a diluent may be required.
Ventolin nebules are to be used with a nebuliser, under the direction of a physician.
The solution must not be injected or swallowed.
Delivery of the aerosol may be by facemask, "T" piece or via endotracheal tube. Intermittent positive pressure ventilation may be used but is rarely necessary. When there is a risk of anoxia through hypoventilation, oxygen should be added to the inspired air.
As many nebulisers operate on a continuous flow basis, it is likely that nebulised drug will be released in the local environment. Ventolin Respiratory solution should therefore be administered in a well ventilated room, particularly in hospitals when several patients may be using nebulisers at the same time.
Clinical efficacy of nebulised salbutamol in infants <18 months is uncertain. As transient hypoxaemia may occur, supplemental oxygen therapy should be considered.
Dilution: Ventolin nebules may be diluted with sterile normal saline. Any unused solution in the chamber of the nebuliser must be discarded.
Ampoule: Salbutamol has a duration of action of 4-6 hrs in most patients.
Ventolin parenteral preparations are to be used under the direction of a physician.
Note: The contents of the ampoules of Ventolin solution for IV infusion must not be injected undiluted. The concentration should be reduced by 50% before administration.
Ventolin parenteral preparations should not be administered in the same syringe or infusion as any other medication.
Adults: Severe Bronchospasm and Status Asthmaticus: SC: 500 mcg (8 mcg/kg body weight) and repeated every 4 hrs as required.
IM: 500 mcg (8 mcg/kg body weight) and repeated every 4 hrs as required.
IV: 250 mcg (4 mcg/kg body weight) injected slowly. If necessary, the dose may be repeated.
If Ventolin injection 500 mcg in 1 ML (500 mcg/mL) is used, the injection may be facilitated by dilution with water for injections.
Infusion: In status asthmaticus, infusion rates of 3-20 mcg/min are generally adequate but in patients with Respiratory failure, higher dosage has been used with success. A starting dose of 5 mcg/min is recommended with appropriate adjustment in dosage according to patient response.
A suitable solution for infusion may be prepared by diluting 5 mL of Ventolin solution for IV infusion in 500 mL of an infusion solution eg, sodium chloride and dextrose injection BP to provide a salbutamol dose of 10 mcg/mL of solution.
Management of Premature Labour: For this indication, Ventolin solution for IV infusion is recommended using a solution prepared as mentioned previously. Infusion rates of 10-45 mcg/min are generally adequate to control uterine contractions but greater or lesser infusion rates may be required according to the strength and frequency of contractions. A starting rate of 10 mcg/min is recommended, increasing the rate at 10-min intervals until there is evidence of patient response shown by diminution in strength, frequency or duration of contractions. Thereafter, the infusion rate may be increased slowly until contractions cease. The maternal pulse rate should be monitored and the infusion rate adjusted to avoid excessive maternal heart rates (>140 bpm).
Once uterine contractions have ceased, the infusion rate should be maintained at the same level for 1 hr and then reduced by 50% decrements at 6-hourly intervals. Treatment may be continued orally with Ventolin tablets 4 mg given 3 or 4 times daily.
As an alternative procedure or to counteract inadvertent overdosage with oxytocic drugs, Ventolin injection may be administered as a single injection by the IV or IM routes. The usual recommended dose is 100-250 mcg of salbutamol. The dose may be repeated according to the response of the patient.
Children: At present, there is insufficient evidence to recommend a dosage regimen for routine use in children.
Dilution: Ventolin parenteral preparations may be diluted with water for injections BP, sodium chloride injection BP, sodium chloride and dextrose injection BP or dextrose injection BP. These are the only recommended diluents.

Overdose

Most common overdose signs and symptoms are transient β-agonist pharmacologically mediated events.
During continuous administration of Ventolin Respiratory solution, any signs of overdosage can usually be counteracted by withdrawal of the drug.
Hypokalaemia may occur following overdose with salbutamol. Serum potassium levels should be monitored. Nausea, vomiting and hyperglycaemia have been reported, predominantly in children and when salbutamol overdose has been taken via the oral route.
Treatment consists of discontinuation of salbutamol together with appropriate symptomatic therapy eg, cardioselective β-blocking agents in patients representing with cardiac symptoms (eg, tachycardia, palpitations). β-blocking drugs should be used with caution in patients with a history of bronchospasm.

Contraindications

History of hypersensitivity to any of the components of Ventolin.
Although IV salbutamol and occasionally salbutamol tablets are used in the management of premature labour, uncomplicated by conditions eg, placenta praevia, antepartum haemorrhage or toxaemia of pregnancy, inhaled salbutamol preparation are not appropriate for managing premature labour. Salbutamol presentations should not be used for threatened abortion.

Special Precautions

Ampoule: Bronchodilators should not be the only or main treatment in patients with severe or unstable asthma. Severe asthma requires regular medical assessment as death may occur. Patients with severe asthma have constant symptoms and frequent exacerbations, with limited physical capacity and PEF values <60% predicted at baseline with >30% variability, usually not returning entirely to normal after a bronchodilator. These patients will require high dose inhaled (eg, >1 mg/day beclomethasone dipropionate) or oral corticosteroid therapy. Sudden worsening of symptoms may require increased corticosteroid dosage which should be administered under urgent medical supervision.
The management of asthma should normally follow a stepwise programme and patient response should be monitored clinically and by lung function tests.
Increasing use of short-acting inhaled β2-agonists to control symptoms indicates deterioration of asthma control. Sudden and progressive deterioration in asthma control is potentially life-threatening and consideration should be given to starting or increasing corticosteroid therapy. In patients considered at risk, daily peak flow monitoring may be instituted.
Patients should be warned that if either the usual relief is diminished or the usual duration of action reduced, they should not increase the dose or its frequency of administration, but should seek medical advice.
Salbutamol should be administered cautiously to patients with thyrotoxicosis.
As maternal pulmonary oedema and myocardial ischaemia have been reported during or following treatment of premature labour with β2-agonists, careful attention should be given to fluid balance and cardioRespiratory function including ECG should be monitored. If signs of pulmonary oedema or myocardial ischaemia develop, discontinuation of treatment should be considered.
Potentially serious hypokalaemia may result from β2-agonist therapy mainly from parenteral and nebulised administration. Particular caution is advised in acute severe asthma as this effect may be potentiated by concomitant treatment with xanthine derivatives, steroids, diuretics and by hypoxia. It is recommended that serum potassium levels are monitored in such situations.
In common with other β-adrenoceptor agonists, Ventolin can induce reversible metabolic changes eg, increased blood sugar levels. The diabetic patient may be unable to compensate for this and the development of ketoacidosis has been reported. Concurrent administration of corticosteroids can exaggerate this effect.
Ventolin oral liquid: Not indicated for obstretic use.
Respiratory Solution: Ventolin Respiratory solution should be used with care in patients known to have received large doses of other sympathomimetic drugs.
Nebules: A small number of cases of acute angle closure glaucoma have been reported in patients treated with a combination of nebulised salbutamol and ipratropium bromide. A combination of nebulised salbutamol with nebulised anticholinergics should therefore be used cautiously. Patients should receive adequate instruction in correct administration and be warned not to let the solution or mist enter the eye.
Respiratory Solution/Ampoule/Nebules: Lactic acidosis has been reported very rarely in association with high therapeutic doses of IV and nebulised short-acting β-agonist therapy, mainly in patients being treated for an acute asthma exacerbation. Increase in lactate levels may lead to dyspnoea and compensatory hyperventilation, which could be misinterpreted as a sign of asthma treatment failure and lead to inappropriate intensification of short-acting β-agonist treatment. It is therefore recommended that patients are monitored for the development of elevated serum lactate and consequent metabolic acidosis in this setting.
Evohaler: In the event of previously effective dose of inhaled salbutamol failing to give relief for at least 3 hrs, the patient should be advised to seek medical advice in order that any necessary additional steps may be taken.
Patient's inhaler technique should be checked to make sure that aerosol actuation is synchronised with inspiration of breath for optimum delivery of the drug to the lungs.
Ampoule: The use of Ventolin parenteral preparations in the treatment of severe bronchospasm or status asthmaticus does not obviate the requirement for glucocorticoid steroid therapy as appropriate.
When practicable, administration of oxygen concurrently with parenteral Ventolin is recommended, particularly when it is given by IV infusion to hypoxic patients.
Diabetic patients and those concurrently receiving corticosteroids should be monitored frequently during IV infusion of Ventolin so that remedial steps (eg, an increase in insulin dosage) can be taken to counter any metabolic change occurring. For these patients, Ventolin solution for intravenous infusion should be diluted with sodium chloride injection BP, rather than sodium chloride and dextrose injection BP.
In the treatment of premature labour by IV infusion of salbutamol, increases in maternal heart rate of the order 20-50 bpm usually accompany the infusion. The maternal pulse rate should be monitored and not normally allowed to exceed a steady rate of 140 bpm.
Maternal blood pressure may fall slightly during the infusion; the effect being greater on diastolic than on systolic pressure. Falls in diastolic pressure are usually within the range of 10-20 mm Hg. The effects of infusion on foetal rate is less marked but increases of up to 20 bpm may occur.
In the treatment of premature labour, before Ventolin parenteral preparations are given to any patient with known heart disease, an adequate assessment of the patient's cardiovascular status should be made by a physician experienced in cardiology.
Effects on the Ability to Drive or Operate Machinery: None reported.
Use in pregnancy: Administration of drugs during pregnancy should only be considered if the expected benefit to the mother is greater than any possible risk to the foetus.
Oral liquid/Respiratory Solution/Evohaler/Ampoule: During worldwide marketing experience, rare cases of congenital anomalies, including cleft palate and limb defects have been reported in the offspring of patients being treated with salbutamol. Some of the mothers were taking multiple medications during their pregnancies. Because no consistent pattern of defects can be discerned and baseline rate for congenital anomalies is 2-3%, a relationship with salbutamol use cannot be established.
Use in lactation: As salbutamol is probably secreted in breast milk, its use in nursing mothers is not recommended unless the expected benefits outweigh any potential risk. It is not known whether salbutamol in breast milk has a harmful effect on the neonate.

Adverse Drug Reactions

Immune System Disorders: Very rare: Hypersensitivity reactions including angioedema, urticaria, bronchospasm, hypotension and collapse.
Metabolism and Nutrition Disorders: Rare: Hypokalaemia. Potentially serious hypokalaemia may result in β2-agonist therapy. Very Rare: Lactic acidosis (Respiratory solution/ampoule/nebules).
Nervous System Disorders: Very Common: Tremor. Common: Headache. Very Rare: Hyperactivity.
Cardiac Disorders: Common: Tachycardia, palpitations. Uncommon: Myocardial ischaemia (in the management of pre-term labour with Ventolin injection/solution for infusion). Rare: Cardiac arrhythmias including atrial fibrillation, supraventricular tachycardia and extrasystoles.
Vascular Disorders: Rare: Peripheral vasodilatation.
Respiratory, Thoracic and Mediastinal Disorders: Uncommon: Pulmonary oedema (ampoule). Very Rare: Paradoxical bronchospasm (Evohaler).
Gastrointestinal Disorders: Uncommon: Mouth and throat irritation (Evohaler). Very Rare: Nausea, vomiting (ampoule).
Musculoskeletal and Connective Tissue Disorders: Common: Muscle cramps. Very Rare: Feeling of muscle tension (tablet and oral liquid).
Injury, Poisoning and Procedural Complications: Very Rare: Slight pain or stinging on IM use of undiluted injection (ampoule).
Ampoule: In the management of pre-term labour, Ventolin injection has uncommonly been associated with pulmonary oedema. Patients with predisposing factors including multiple pregnancies, fluid overload, maternal infection and preeclampsia may have an increased risk of developing pulmonary oedema.
Ampoule: In the management of premature labour, IV infusion of Ventolin has rarely been associated with nausea and vomiting.
Respiratory Solution/Nebules/Evohaler: As with other inhalation therapy, paradoxical bronchospasm may occur with an immediate increase in wheezing after dosing. This should be treated immediately with an alternative presentation or a different fast-acting inhaled bronchodilator. Ventolin should be discontinued immediately, the patient assessed and if necessary, alternative therapy instituted.

Drug Interactions

Increased theophylline toxicity with propranolol, cimetidine, erythromycin, quinolone antibiotics. Reduced efficacy with rifampicin, phenobarbitone, phenytoin, carbamazepine, sulfinpyrazone and smoking. Increased risk of hypokalaemia with diuretics. Potentially Fatal: With anaesthetics, pancuronium bromide and sympathomimetics (increased risk of arrhythmias).

Food Interaction

Absorption of theophylline reduced variably by different types of food.

Lab Interference

Theophylline may cause spurious elevations of serum uric acid and increase in urinary catecholamines.

Storage

Tablet: Store below 25°C.
Syrup: Store at a temperature not exceeding 30°C. Protect from light.
Respiratory Solution: Store below 25°C. Protect from light. Once the bottle has been opened, the contents should be discarded after 1 month.
Evohaler: Store below 30°C. Protect from frost and direct sunlight.
As with most inhaled medications in aerosol canisters, the therapeutic effect of this medication may decrease when the canister is cold. The canister should not be broken, punctured or burnt, even when apparently empty.
Nebule: Store at a temperature below 30°C. Protect from light.
Ampoule: Store at a temperature below 30°C. Protect from light.

Pharmacology

Pharmacology: Pharmacodynamics: Salbutamol is a selective β2-adrenoceptor agonist. At therapeutic doses, it acts on the β2-adrenoreceptors of bronchial muscle, with little or no action on the β1-adrenoreceptors of cardiac muscle.
Because of their selective action on the bronchi and their lack of effects on the cardiovascular system, Ventolin oral preparations are suitable for treating bronchospasm in patients with coexisting heart disease or hypertension.
The selective action of salbutamol on the β2-adrenoceptors has led to the use of parenteral Ventolin, usually as a continuous IV infusion, for the management of premature labour during the 3rd trimester of pregnancy. Once the uterine contractions have ceased and the infusion of Ventolin has been gradually withdrawn, maintenance therapy can be effected with Ventolin tablets.
Evohaler: Salbutamol provides short-acting (4-6 hrs) bronchodilation with a fast onset (within 5 min) in reversible airways obstruction.
Pharmacokinetics: Salbutamol administered IV has a t½ of 4-6 hrs and is cleared partly renally and partly by metabolism to the inactive 4'-O-sulphate (phenolic sulphate) which is also excreted primarily in the urine. The faeces are a minor route of excretion. The majority of a dose of salbutamol given IV, orally or by inhalation is excreted within 72 hrs. Salbutamol is bound to plasma proteins to the extent of 10%.
After oral administration, salbutamol is absorbed from the GIT and undergoes considerable first-pass metabolism to the phenolic sulphate. Both unchanged drug and conjugate are excreted primarily in the urine. The bioavailability of orally administered salbutamol is about 50%.
Evohaler: After administration by the inhaled route, 10% and 20% of dose reach the lower airways. The remainder is retained in the delivery system or is deposited in the oropharynx from where it is swallowed. The fraction deposited in the airways is absorbed into the pulmonary tissues and circulation but it is not metabolized by the lung. On reaching the systemic circulation, salbutamol becomes accessible to hepatic metabolism and is excreted primarily in the urine, as unchanged drug and as the phenolic sulphate. The swallowed portion of an inhaled dose is absorbed from the GIT and undergoes considerable first-pass metabolism to the phenolic sulphate. Both unchanged drug and conjugate are excreted primarily in the urine.

ATC Classification

R03AC02 - salbutamol; Belongs to the class of adrenergic inhalants, selective beta-2-adrenoreceptor agonists. Used in the treatment of obstructive airway diseases. R03CC02 - salbutamol; Belongs to the class of adrenergics for systemic use, selective beta-2-adrenoreceptor agonists. Used in the treatment of obstructive airway diseases. R03DA04 - theophylline; Belongs to the class of other systemic drugs used in the treatment of obstructive airway diseases, xanthines.

 

Brand/Product Info


Total Products : 98                                                                                                  
Brand Name Manufacturer/Marketer Composition Dosage Form Pack Size & Price
ACTOLIN Globe Pharmaceuticals Ltd Salbutamol 2mg/5ml Syrup 100ml: 15.00 MRP
ALVOLEX Silva Pharmaceuticals Limited Salbutamol 2mg/5ml Syrup 100ml: 16.07 MRP
ASMALIN HFA Aristopharma Ltd. Salbutamol 100mcg/puff Inhaler (MDI) 200 MDI: 175.00 MRP
ASMALIN HFA (Refill) Aristopharma Ltd. Salbutamol 100mcg/puff Inhaler (Refill Can) 200 doses canister: 155.00 MRP
ASMATOL Rephco Laboratories Ltd. Salbutamol 2mg/5ml Syrup 60ml: 14.45 MRP
ASMOLEX Aristopharma Ltd. Salbutamol 2mg/5ml Syrup 100ml: 22.92 MRP
ASNIL Ziska Pharmaceuticals Ltd. Salbutamol 2mg/5ml Syrup 100ml: 16.00 MRP
ASTHMOLIN Pharmadesh Laboratories Limited Salbutamol 2mg Tablet 100's: 28.00 MRP
ASTHMOLIN Syrup Pharmadesh Laboratories Limited Salbutamol 2mg/5ml Syrup 60ml, 100ml: 11.38 & 21.08 MRP
ASUL Asiatic Laboratories Ltd. Salbutamol 2mg/5ml Syrup 100ml: 22.92 MRP
AZMAREL Euro Pharma Ltd. Salbutamol 2mg & 4mg Tablet 100's each: 26.00 & 34.00 MRP
AZMAREL Syrup Euro Pharma Ltd. Salbutamol 2mg/5ml Syrup 100ml: 22.00 MRP
AZMASOL 2 Beximco Pharmaceuticals Ltd Salbutamol Sulphate BP eq. to 2mg Salbutamol Tablet 500's: 130.00 MRP
AZMASOL 200 REFILL Beximco Pharmaceuticals Ltd Salbutamol 100mcg/puff Inhaler Refill 200MD: 150.00 MRP
AZMASOL 4 Beximco Pharmaceuticals Ltd Salbutamol Sulphate BP eq. to 4mg Salbutamol Tablet 500's: 200.00 MRP
AZMASOL BEXICAP Beximco Pharmaceuticals Ltd Salbutamol 0.20mg Capsule 30's: 75.00 MRP
AZMASOL HFA 200 Beximco Pharmaceuticals Ltd Salbutamol 100mcg/puff Inhaler 200MD: 180.00 MRP
AZMASOL HFA 300 Beximco Pharmaceuticals Ltd Salbutamol 100mcg/puff Inhaler 300MD: 260.00 MRP
AZMASOL SOLUTION Beximco Pharmaceuticals Ltd Salbutamol Sulphate 5mg/ml (i.e.0.5%) Solution 20ml: 120.00 MRP
AZMET Medicon Laboratories Ltd Salbutamol 2mg/5ml Syrup 60ml, 100ml: 15.00 & 22.00 MRP
BROAD Nipa Pharmaceuticals Ltd. Salbutamol 2mg/5ml Syrup 100ml: 15.00 MRP
BRODIL ACI Ltd. Salbutamol 2mg & 4mg Tablet 500's each: 130.00 & 200.00 MRP
BRODIL HFA ACI Ltd. Salbutamol 100mcg/puff Inhaler (MDI) 200 MDI: 175.66 MRP
BRODIL HFA (Refill) ACI Ltd. Salbutamol 100mcg/puff Inhaler (Refill Can) 200 doses can: 155.58 MRP
BRODIL Inhaler ACI Ltd. Salbutamol 100mcg/puff Inhaler (MDI) 200 MDI: 160.00 MRP
BRODIL Syrup ACI Ltd. Salbutamol 2mg/5ml Syrup 100ml: 22.93 MRP
BROLAX Somatec Pharmaceuticals Ltd. Salbutamol 2mg & 4mg Tablet 400's each: 25.00 & 33.00 MRP
BROLAX Syrup Somatec Pharmaceuticals Ltd. Salbutamol 2mg/5ml Syrup 100ml: 15.06 MRP
BRONCOTROL Pacific Pharmaceuticals Ltd. Salbutamol 2mg/5ml Syrup 100ml: 16.11 MRP
BRONCOTROL 4 Pacific Pharmaceuticals Ltd. Salbutamol 4mg Tablet 200's: 68.00 MRP
BRONDYL Millat Pharmaceuticals Ltd Salbutamol 2mg/5ml Syrup 100ml: 22.80 MRP
BRONIL-S Seema Pharmaceuticals Ltd. Salbutamol 2mg/5ml Syrup 100ml: 22.00 MRP
BRONKOLAX Beximco Pharmaceuticals Ltd Salbutamol Sulphate BP eq. to Salbutamol 2mg/5ml Syrup 100ml: 22.93 MRP
D-BUTAMOL Doctors Chemical Works Ltd Salbutamol 2mg/5ml Syrup 100ml: 22.80 MRP
DECABUTAMOL Decent Pharma Laboratories Ltd. Salbutamol 2mg/5ml Syrup 60ml, 100ml: 12.00 & 21.83 MRP
DILATOL Kemiko Pharmaceuticals Ltd Salbutamol 2mg/5ml Syrup 100ml: 22.84 MRP
ETOL Edruc Limited Salbutamol 2mg/5ml Syrup 100ml: 22.00 MRP
G-SALBUTAMOL Gonoshasthaya Pharmaceuticals Ltd Salbutamol 4mg Tablet 100's: 35.00 MRP
G-SALBUTAMOL Injection Gonoshasthaya Pharmaceuticals Ltd Salbutamol 50mcg Injection 20ml vial: 101.53 MRP
G-SALBUTAMOL Syrup Gonoshasthaya Pharmaceuticals Ltd Salbutamol 2mg/5ml Syrup 100ml: 15.05 MRP
H-SELAX Hudson Pharmaceuticals Ltd Salbutamol 4mg Tablet 100's: 34.00 MRP
H-SELAX Syrup Hudson Pharmaceuticals Ltd Salbutamol 2mg/5ml Syrup 60ml, 100ml: 10.80 & 15.00 MRP
ORSAL Orion Pharma Ltd. Salbutamol 2mg/5ml Syrup 100ml: 22.85 MRP
PULMOLIN Opsonin Pharma Limited Salbutamol 4mg Tablet 100's: 33.00 MRP
PULMOLIN Syrup Opsonin Pharma Limited Salbutamol 2mg/5ml Syrup 60ml, 100ml: 10.45 & 22.85 MRP
RESDIL Cosmo Pharma Laboratories Ltd. Salbutamol 4mg Tablet 200's: 66.00 MRP
RESPOLIN Jayson Pharmaceuticals Ltd. Salbutamol 4mg Tablet 100's: 25.00 MRP
RESPOLIN Syrup Jayson Pharmaceuticals Ltd. Salbutamol 2mg/5ml Syrup 100ml: 22.92 MRP
SABUL Chemist Laboratories Ltd. Salbutamol sulphate 5mg/ml Nebuliser Solution 20ml: 110.00 MRP
SALBU Biopharma Laboratories Ltd Salbutamol 2mg & 4mg Tablet 100's each: 26.00 & 34.00 MRP
SALBU Syrup Biopharma Laboratories Ltd Salbutamol 2mg/5ml Syrup 60ml, 100ml: 11.04 & 22.93 MRP
SALBUMOL Indo-Bangla Pharmaceuticals Works Ltd. Salbutamol 2mg/5ml Syrup 100ml: 16.00 MRP
SALBUT General Pharmaceuticals Ltd Salbutamol 2mg/5ml Syrup 100ml: 22.90 MRP
SALBUTAL Sanofi Salbutamol 2mg & 4mg Tablet 500's each: 130.01 & 169.97 MRP
SALBUTAL Syrup Sanofi Salbutamol 2mg/5ml Syrup 100ml: 22.89 MRP
SALBUTAMOL Bristol Pharma Limited Salbutamol 2mg & 4mg Tablet 500's each: 130.00 & 170.00 MRP
SALBUTAMOL Syrup Amico Laboratories Ltd. Salbutamol 2mg/5ml Syrup 100ml: 21.75 MRP
SALIX Modern Pharmaceuticals Ltd Salbutamol 4mg Tablet 100's: 34.00 MRP
SALIX-4 Modern Pharmaceuticals Ltd Salbutamol 2mg/5ml Syrup 60ml, 100ml: 10.80 & 22.90 MRP
SALMOL Medimet Pharmaceuticals Ltd Salbutamol 4mg Tablet 100's: 34.00 MRP
SALMOL Syrup Medimet Pharmaceuticals Ltd Salbutamol 2mg/5ml Syrup 60ml, 100ml: 13.00 & 20.00 MRP
SALMOLIN The Acme Laboratories Ltd. Salbutamol 4mg Tablet 100's: 34.00 MRP
SALMOLIN 200 The Acme Laboratories Ltd. Salbutamol 200mcg/rotacap Inhaler (DPI) 30 & 100 caps: 37.50 & 125.00 MRP
SALMOLIN Inhaler The Acme Laboratories Ltd. Salbutamol 100mcg/puff Inhaler (MDI) 200 MDI: 180.68 MRP
SALMOLIN Resp Soln The Acme Laboratories Ltd. Salbutamol sulphate 5mg/ml Inhalation Solution 20ml: 120.00 MRP
SALMOLIN Syrup The Acme Laboratories Ltd. Salbutamol 2mg/5ml Syrup 60ml, 100ml: 10.83 & 22.93 MRP
SALOL Cosmic Chemical Industries Limited Salbutamol 2mg/5ml Syrup 100ml: 22.00 MRP
SALOMAX 100 Eskayef Bangladesh Ltd Salbutamol 100mcg/puff, 200MD Inhaler (MDI) 200 MDI, MRP: 160.00
SULBLON Kumudini Pharma Ltd Salbutamol 2mg/5ml Syrup 100ml: 22.00 MRP
SULTOLIN 4 Square Pharmaceuticals Ltd. Salbutamol 4mg Tablet 20x10's: 92.00 MRP
SULTOLIN COZYCAP Square Pharmaceuticals Ltd. Salbutamol 200 mcg Cozycap 5x6's: 75.30 MRP
SULTOLIN HFA Square Pharmaceuticals Ltd. Salbutamol 100 mcg/puff HFA Inhaler (CFC-Free) 200 puffs: 195.59 MRP
SULTOLIN HFA REFILL Square Pharmaceuticals Ltd. Salbutamol 100 mcg/puff HFA Refill (CFC-Free) 200 puffs: 170.51 MRP
SULTOLIN RESP Square Pharmaceuticals Ltd. Salbutamol 5mg/ml Respirator Solution 20 ml: 120.82 MRP
SULTOLIN SR-TAB Square Pharmaceuticals Ltd. Salbutamol 8mg Tablet 20x10's: 184.00 MRP
SULTOLIN SYP Square Pharmaceuticals Ltd. Salbutamol 2mg/5 ml Syrup 100 ml: 23.00 MRP
TOLIN Mystic Pharmaceuticals Limited Salbutamol 4mg Tablet 100's: 34.00 MRP
TOLIN Syrup Mystic Pharmaceuticals Limited Salbutamol 2mg/5ml Syrup 100ml: 15.00 MRP
VENLET Apollo Pharmaceutical Laboratories Ltd. Salbutamol 2mg/5ml Syrup 100ml: 15.00 MRP
VENTISAL IBN SINA Pharmaceutical Industry Ltd. Salbutamol 4mg Tablet 100's: 34.00 MRP
VENTISAL Syrup IBN SINA Pharmaceutical Industry Ltd. Salbutamol 2mg/5ml Syrup 100ml: 22.92 MRP
VENTOL CPL Central Pharmaceuticals Ltd Salbutamol 2mg/5ml Syrup 60ml, 100ml: 10.50 & 15.00 MRP
VENTOL Syrup Gaco Pharmaceutical Ltd. Salbutamol 2mg/5ml Syrup 100ml: 10.50 MRP
VENTOLEX Desh Pharmaceuticals (Pvt) Ltd Salbutamol 2mg/5ml Syrup 100ml: 16.00 MRP
VENTOLEX-4 Desh Pharmaceuticals (Pvt) Ltd Salbutamol 4mg Tablet 500's: 170.00 MRP
VENTOLIN GlaxoSmithKline Bangladesh Limited Salbutamol 2mg & 4mg Tablet 500's each: 131.67 & 172.23 MRP
VENTOLIN HFA GlaxoSmithKline Bangladesh Limited Salbutamol 100mcg/puff Evohaler (MDI) 200 MDI: 200.00 MRP
VENTOLIN Nebuliser Soln GlaxoSmithKline Bangladesh Limited Salbutamol sulphate 2.5mg/2.5ml Nebuliser Solution 2.5ml x30's: 803.40 MRP
VENTOLIN Resp Soln GlaxoSmithKline Bangladesh Limited Salbutamol sulphate 5mg/ml Inhalation Solution 20ml: 172.90 MRP
VENTOLIN Syrup GlaxoSmithKline Bangladesh Limited Salbutamol 2mg/5ml Syrup 100ml: 22.93 MRP
VENTOLIN-SR GlaxoSmithKline Bangladesh Limited Salbutamol 8mg Tablet (sustained release) 250's: 194.84 MRP
VENTOSOL Ad-din pharmaceuticals Ltd. Salbutamol 2mg/5ml Syrup 100ml: 20.00 MRP
Windel 2 Incepta Pharmaceuticals Limited Salbutamol Sulphate BP equivalent to 2mg Salbutamol Tablet 20x10's:MRP 52 Tk
Windel 4 Incepta Pharmaceuticals Limited Salbutamol Sulphate BP equivalent to 4mg Salbutamol Tablet 20x10's:MRP 68 Tk
Windel Nebuliser Soln Incepta Pharmaceuticals Limited Salbutamol Sulphate BP equivalent to Salbutamol 2.5mg/2.5ml Nebuliser solution 10x1's:MRP 140 Tk
WINDEL Resp Soln Incepta Pharmaceuticals Limited Salbutamol Sulphate BP equivalent to Sulbutamol 5mg/ml Inhalation Solution 1's: 120.00 MRP
Windel Syrup Incepta Pharmaceuticals Limited Salbutamol Sulphate BP equivalent to Salbutamol 2mg/5ml Syrup 100ml:MRP 22.9 Tk
ZENTOLIN Zenith Pharmaceuticals Ltd. Salbutamol sulphate 2mg/5ml Syrup 60ml, 100ml: 10.00 & 15.60 MRP

Gen. MedInfo

Why this medication is prescribed?

Salbutamol/Albuterol is used to prevent and treat wheezing, difficulty breathing, chest tightness, and coughing caused by lung diseases such as asthma and chronic obstructive pulmonary disease (COPD; a group of diseases that affect the lungs and airways). Salbutamol/Albuterol is in a class of medications called bronchodilators. It works by relaxing and opening the air passages to the lungs to make breathing easier.

How to use this medicine?

Salbutamol (Albuterol) may come as a tablet, a syrup and an extended-release (long-acting) tablet to take by mouth as well as Inhaler or Respiratory Solution. The tablets and syrup are usually taken three or four times a day. The extended-release tablets are usually taken once every 12 hours. Take albuterol at around the same times every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take Salbutamol (Albuterol) exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor. Swallow the extended-release tablets whole with plenty of water or other liquid. Do not split, chew, or crush them. Your doctor may start you on a low dose of Salbutamol (Albuterol) and gradually increase your dose.

Salbutamol (Albuterol) may help control your symptoms but will not cure your condition. Continue to take Salbutamol (Albuterol) even if you feel well. Do not stop taking Salbutamol (Albuterol) without talking to your doctor.

Call your doctor if your symptoms worsen or if you feel that Salbutamol (Albuterol) no longer controls your symptoms.

Other uses 

This medication may be prescribed for other uses; ask your doctor for more information.

What special precautions to follow?

Before taking Salbutamol (Albuterol),

  • tell your doctor  if you are allergic to Salbutamol (Albuterol), any other medications, or any of the ingredients in Salbutamol (Albuterol) tablets, extended-release tablets, or capsules.
  • tell your doctor  what prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: beta blockers such as atenolol, labetalol, metoprolol, nadolol, and propranolol; digoxin; diuretics ('water pills'); epinephrine; other oral and inhaled medications for asthma and medications for colds. Also tell your doctor or pharmacist if you are taking the following medications or have stopped taking them within the past two weeks: antidepressants such as amitriptyline, amoxapine, clomipramine, desipramine, doxepin, imipramine (Tofranil), nortriptyline, protriptyline, and trimipramine; and monoamine oxidase (MAO) inhibitors, including isocarboxazid, phenelzine, selegiline, and tranylcypromine. Your doctor may need to change the doses of your medications or monitor you carefully for side effects.
  • tell your doctor if you have or have ever had an irregular heartbeat, heart disease, high blood pressure, hyperthyroidism (condition in which there is too much thyroid hormone in the body), diabetes, or seizures.
  • tell your doctor if you are pregnant, plan to become pregnant, or are breast-feeding. If you become pregnant while taking Salbutamol (Albuterol), call your doctor.
  • you should know that Salbutamol (Albuterol) sometimes causes wheezing and difficulty breathing. If this happens, call your doctor right away. Do not use Salbutamol (Albuterol) again unless your doctor tells you that you should.

What special dietary instructions to follow?

Unless your doctor tells you otherwise, continue your normal diet.

What to do if I forget a dose?

Take the missed dose as soon as you remember it. However, if it is almost time for the next dose, skip the missed dose and continue your regular dosing schedule. Do not take a double dose to make up for a missed one.

What side effects can this medication cause?

Salbutamol (Albuterol) may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:

  • nervousness
  • shakiness
  • dizziness
  • headache
  • uncontrollable shaking of a part of the body
  • muscle cramps
  • excessive motion or activity
  • sudden changes in mood
  • nosebleed
  • nausea
  • increased or decreased appetite
  • difficulty falling asleep or staying asleep
  • pale skin
  • Some side effects can be serious. If you experience any of these symptoms, call your doctor immediately:
  • fast, pounding, or irregular heartbeat
  • chest pain
  • fever
  • blisters or rash
  • hives
  • itching
  • swelling of the face, throat, tongue, lips, eyes, hands, feet, ankles, or lower legs
  • increased difficulty breathing
  • difficulty swallowing
  • hoarseness

Salbutamol (Albuterol) may cause other side effects. Call your doctor if you have any unusual problems while taking this medication.

What other information to know?

Keep all appointments with your doctor and the laboratory. Your doctor will order certain lab tests to check your response to this medicine.

Do not let anyone else use your medication. If you still have symptoms and need further treatment, consult your doctor.

It is important for you to keep a written list of all of the prescription and nonprescription (over-the-counter) medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements. You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. It is also important information to carry with you in case of emergencies.

 Ref: U.S. Natl. Library of Medicine


This information is provided for reference only and not a replacement for and should only be used in conjunction with full consultation with a registered medical practitioner. It may not contain all the available information you require and cannot substitute professional medical care, nor does it take into account all individual circumstances. Although great effort has been made to ensure content accuracy, mph-bd shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise.

Back to top.